About Us

• CeloNova Biosciences, Inc. develops, manufactures and markets a family of products based upon the unique properties of Polyzene®-F; pairing polymer science innovation with cutting edge devices.
  
  The Company's products are used by Physician’s across the globe to improve patient outcomes in the fields of vascular intervention and embolization. CeloNova’s current product platforms are:
  ■Embozene® Microspheres, a spherical embolic device for the treatment of neurovascular arteriovenous malformations, hepatocellular carcinoma, hypervascularized tumors, and arteriovenous malformations. In addition, Embozene® Microspheres carry a CE Mark approval for use in the treatment of uterine fibroids outside of the US. The spheres consist of a hydrogel center and an outer layer of the Company's proprietary coating, Polyzene®-F which enhances biocompatibility and reduces inflammation. Embozene Microspheres are available in an extensive range of tightly calibrated sizes allowing for precisely targeted embolization and feature the world’s first embolic color-coded by size.
  ■The CATANIA™ Coronary Stent System is approved for the treatment of symptomatic ischemic heart disease due to de novo and obstructive lesions of native coronary arteries. The stent features a NanoThin Polyzene®-F surface treatment which has been shown to promote healthy endothelial cell growth without stimulating platelet activation. The CATANIA™ Coronary Stent System carries a CE Mark and is currently available for sale outside of the United States.